MARKET

RGNX

RGNX

Regenxbio
NASDAQ
10.33
+0.07
+0.68%
After Hours: 10.40 +0.07 +0.68% 18:49 02/06 EST
OPEN
10.73
PREV CLOSE
10.26
HIGH
10.95
LOW
10.32
VOLUME
1.00M
TURNOVER
--
52 WEEK HIGH
16.19
52 WEEK LOW
5.04
MARKET CAP
522.94M
P/E (TTM)
-2.9833
1D
5D
1M
3M
1Y
5Y
1D
REGENXBIO Inc. (NASDAQ:RGNX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
Simply Wall St · 2d ago
Weekly Report: what happened at RGNX last week (0126-0130)?
Weekly Report · 6d ago
Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action
PR Newswire · 01/29 23:06
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
Barchart · 01/29 18:01
REGENXBIO Price Target Maintained With a $52.00/Share by Chardan Capital
Dow Jones · 01/29 13:08
REGENXBIO Is Maintained at Buy by Chardan Capital
Dow Jones · 01/29 13:08
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Armata Pharmaceuticals (ARMP) and Halozyme (HALO)
TipRanks · 01/29 11:30
Is REGENXBIO (NASDAQ:RGNX) Weighed On By Its Debt Load?
Simply Wall St · 01/29 10:31
More
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Webull offers Regenxbio Inc stock information, including NASDAQ: RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.